GeneralLast reviewed April 2026

Bioresearch Monitoring(BIMO)

FDA's program that inspects clinical investigators, sponsors, IRBs, and nonclinical laboratories to verify compliance with applicable regulations.

Usage Examples

A BIMO inspection at a pivotal trial site identified Form 483 observations on informed consent documentation.
The GLP laboratory PAI conducted under BIMO confirmed data integrity of pivotal toxicology studies.

What is BIMO?

The Bioresearch Monitoring (BIMO) program is FDA's on-site inspection program for entities involved in clinical and nonclinical research supporting applications to FDA. BIMO inspections cover clinical investigators (site inspections per 21 CFR 312), clinical sponsors and CROs (sponsor inspections), IRBs, GLP laboratories, and bioequivalence studies.

BIMO inspections typically trigger during review of an NDA, BLA, or PMA when FDA selects specific trials, sites, or facilities to verify. Findings feed directly into application review — data integrity issues or significant GCP/GLP violations can cause rejection of data supporting the application. BIMO Form 483 observations and EIRs follow the same framework as manufacturing inspections. Outcomes can include site or sponsor data exclusion from review, or broader regulatory actions for systemic issues.

Regulatory Context

This term appears most often in general workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 312, 21 CFR 58, 21 CFR 56.

FDAICHHealth Canada

When This Matters

A BIMO inspection at a pivotal trial site identified Form 483 observations on informed consent documentation.
The GLP laboratory PAI conducted under BIMO confirmed data integrity of pivotal toxicology studies.

Common Mistakes

Relying on generic terminology without mapping to the active jurisdiction context.
Skipping cross-links between terms, tools, and active regulatory references.
Failing to maintain a single source of truth for regulatory definitions internally.

Related Regulations

21 CFR 31221 CFR 5821 CFR 56FDCA

Frequently Asked Questions

Clinical investigators (site inspections), clinical sponsors and CROs, IRBs, GLP nonclinical laboratories, bioequivalence facilities, and in vivo bioanalytical labs. BIMO covers the full research-generating infrastructure supporting FDA applications.

BIMO findings feed into the review of the application the inspection was triggered by. Data integrity issues or significant GCP/GLP violations can exclude specific sites or studies from review consideration, potentially making the overall application insufficient for approval.

For-cause (specific complaints or findings), surveillance (routine risk-based selection), and directed (specific application review need). FDA risk-ranks sites and sponsors based on enrollment, prior inspection history, and study complexity.